Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Michael Anthony who wrote (218)	1/10/1998 6:57:00 PM
From: Ian@SI	Read Replies (1) \| Respond to of 1321

Thanks for the response. If the 80/20 breakdown you've seen approximates the general population, then it would be worthwhile to add to my holdings. If the effectiveness in the trials is near 100%, I'd have to suspect that analysis and approval of the treatment will come sooner than currently being communicated by QLT IR. Demographics should also help. The boomers are now approaching 50. I believe that 50% of those over 50 will be affected by AMD sooner or later.